Evidence map›Paper›PMID 35867641›Full record

ArticlePloS one2022

Ozone treatment effectively eliminates SARS-CoV-2 from infected face masks.

Elizabeth Córdoba-Lanús, Omar García-Pérez, Francisco Rodríguez-Esparragón, Carlos J Bethencourt-Estrella, Laura B Torres-Mata, Angeles Blanco, Jesús Villar, Oscar Sanz, Juan J Díaz, José L Martín-Barrasa and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Advances in Ozone-Based Inactivation of SARS-CoV-2: An Updated Review.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Elizabeth Córdoba-LanúsInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain.
Omar García-PérezInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain.
Francisco Rodríguez-EsparragónCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Carlos J Bethencourt-EstrellaInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain.
Laura B Torres-MataResearch Unit Hospital Universitario Dr Negrín, Instituto de Investigación Sanitaria de Canarias (IISC), Las Palmas de Gran Canaria, Spain.ORCID 0000-0003-3304-4176
Angeles BlancoChemical Engineering & Materials Department, Universidad Complutense, Madrid, Spain.
Jesús VillarResearch Unit Hospital Universitario Dr Negrín, Instituto de Investigación Sanitaria de Canarias (IISC), Las Palmas de Gran Canaria, Spain.
Oscar SanzFundación Canaria del Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria Spain.ORCID 0000-0002-6107-3559
Juan J DíazFundación Canaria del Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria Spain.
José L Martín-BarrasaResearch Unit Hospital Universitario Dr Negrín, Instituto de Investigación Sanitaria de Canarias (IISC), Las Palmas de Gran Canaria, Spain.
Pedro Serrano-AguilarRETIC de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Instituto de Salud Carlos III, Madrid, Spain.
José-Enrique PiñeroInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain.
Bernardino ClavoCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Jacob Lorenzo-MoralesInstituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, La Laguna, Tenerife, Spain.
Universidad de La Laguna · ESInstituto de Salud Carlos III · ESFundación Canaria de Investigación Sanitaria · ESUniversidad de Las Palmas de Gran Canaria · ESSt. Michael's Hospital · CAUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current COVID-19 pandemic is causing profound health, economic, and social problems worldwide. The global shortage of medical and personal protective equipment (PPE) in specialized centers during the outbreak demonstrated the need for efficient methods to disinfect and recycle them in times of emergency. We have previously described that high ozone concentrations destroyed viral RNA in an inactivated SARS-CoV-2 strain within a few minutes. However, the efficient ozone dosages for active SARS-CoV-2 are still unknown. The present study aimed to evaluate the systematic effects of ozone exposure on face masks from hospitalized patients infected with SARS-CoV-2. Face masks from COVID-19 patients were collected and treated with a clinical ozone generator at high ozone concentrations in small volumes for short periods. The study focused on SARS-CoV-2 gene detection (assessed by real-time quantitative polymerase chain reaction (RT-qPCR)) and on the virus inactivation by in vitro studies. We assessed the effects of different high ozone concentrations and exposure times on decontamination efficiency. We showed that high ozone concentrations (10,000, 2,000, and 4,000 ppm) and short exposure times (10, 10, and 2 minutes, respectively), inactivated both the original strain and the B.1.1.7 strain of SARS-CoV-2 from 24 contaminated face masks from COVID-19 patients. The validation results showed that the best condition for SARS-CoV-2 inactivation was a treatment of 4,000 ppm of ozone for 2 minutes. Further studies are in progress to advance the potential applications of these findings.

Indexed as

COVID-19OzoneHumansMasksPandemicsSARS-CoV-2Ozone

Identifiers

PMID35867641
PMCPMC9307172
OpenAlexW4286587520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.